Kornimate/medical-research-clean huggingface dataset:
biobehavioral effects of topiramate on cannabis-related outcomes in adolescents

Conditions: Cannabis Abuse; Cannabis Dependence

Summary: cannabis use is a significant public health concern that disproportionately affect youth. although promising psychosocial interventions are being developed, most youth do not benefit from these interventions alone. given the clinical demand for effective treatments, the national institute on drug abuse (nida) identified the critical need for data on the tolerability and potential efficacy of medications in adolescents. the purpose of this two-year study is to test if and how topiramate, a medication under intense study for treating several drugs of abuse, reduces cannabis use among teenagers. to this end, the investigators will randomize 56 nontreatment-seeking regular cannabis users (15 or 20 years old) to receive topiramate or placebo for 6 weeks. youth will monitor their cannabis use for the 6-week period using handheld electronic diaries and complete assessments of reactivity to cannabis-related cues.


Eligibility criteria:
inclusion criteria: * 15 to 20 years old (inclusive) * non-treatment seeking for cannabis abuse or dependence * able to read english, understand their rights as provided by the informed consent process, and be willing to sign an informed consent form to participant in the study * if younger than 18 years old, informed consent from a parent or legal guardian is required * used cannabis at least 2 days per week during the past 30 days exclusion criteria: * treatment seeking or a recent history of treatment for cannabis abuse or dependence * endorses a current commitment to stop using cannabis * clinically significant physical abnormalities as indicated by physical exam, hematological assessment, bilirubin concentration or urinalysis * history of renal impairment, renal stones, seizures, or unstable hypertension * underweight (i.e., less than the 5th percentile) or overweight (equal to or greater than the 95th percentile), as determined by the body mass index * positive urine toxicology screen for narcotics, amphetamines, or sedative hypnotics or self-reported drug use, other than cannabis, alcohol or nicotine, in the past 30 days * pregnant, nursing, or refusal to use reliable barrier method of birth control (e.g., condom), if female * took a psychotropic medication in the past 30 days * taking medications with a potential effect on cannabis use or a carbonic anhydrase inhibitor * suicidal * a current dsm-iv-tr axis i diagnosis other than attention- deficit/hyperactivity disorder or a disruptive behavior disorder * a current substance use disorder other than a cannabis, alcohol, and nicotine use disorders * significant alcohol withdrawal symptoms * known sensitivity to topiramate
a novel positron emission tomography (pet) approach to measuring myocardial metabolism

Conditions: Type 2 Diabetes Mellitus

Summary: studies of myocardial fuel selection using a novel palmitate-based pet probe

a novel positron emission tomography (pet) probe, 16- 18-f-fluoro-4-thiapalmitate, will be used to evaluate myocardial atty acid uptake. studies will be done in humans with type 2 diabetes mellitus, and in controls. studies will take place on 2 separate days, under fasting conditions and under insulin clamp conditions.

Eligibility criteria:
inclusion criteria: * lean: * bmi\<25 kg/m2 * normal glucose tolerance by 75g oral glucose tolerance test * type 2 diabetes mellitus: * bmi \>25 kg/m2 * previously diagnosed type 2 diabetes mellitus * on oral and/or injected insulin treatment. exclusion criteria: * lean: \*use of any chronic medications * type 2 diabetes mellitus * known microvascular disease * known coronary or other macro vascular disease * use of ppargamma class antidiabetic agents within 6 months
tolerability of antistax® in patients suffering from chronic venous insufficiency (cvi)

Conditions: Venous Insufficiency

Summary: main objective: safety and tolerability of antistax® film coated tablets secondary objective: effect of antistax® film coated tablets on subjective symptoms of chronic venous insufficiency


Eligibility criteria:
inclusion criteria: * chronic venous insufficiency stage i or ii according to widmer, e.g., resulting in lower-leg oedema * male or female out-patients of any ethnic origin * age ranging from 25 to 75 years exclusion criteria: * known hypersensitivity to any ingredients of the study medication * oedema(s) of non-venous origin, e.g., due to cardiac insufficiency, lymphoedema or decompensated cardiac insufficiency, orthopaedic disturbances * florid venous ulcers * arterial occlusive disease, irrespective of the severity * phlebitis or thrombophlebitis * clinical indication for an acute phlebologic intervention, e.g., compressive treatment, phlebectomy, etc. * evidence of diabetic micro-angiopathy or polyneuropathy in medical history * poor general health (based on the investigator's judgement) * addiction to alcohol abuse * mental illness and inability (or limited ability) to work, or inability (or limited ability) to follow spoken or written explanations concerning the trial * women of child-bearing age not using any reliable contraceptive methods * pregnant or lactating women * patients previously enrolled in the present study or participating in another clinical study, or who had taken part in another study within the previous 90 days * patients receiving compression therapy, high-ceiling diuretics (e.g., furosemide), or any other anti-cvi preparations (e.g., vasoprotectives to treat varicosis, such as heparin-containing preparations, sclerosing agents, or bioflavonoids other than the study medication) during the trial. medications or measures for cvi had to be stopped 14 day prior to intake of study medication.
endometrial markers in autoimmune diseases

Conditions: Endometrial Receptivity; Fertility; Autoimmune Diseases

Summary: autoimmune diseases cause a decreased endometrial receptivity during the implantation window, most likely changing the endometrial cytokines pattern due to dysregulation of the inflammatory processes.therefore, endometrial cytokine profiles will be compared in women with autoimmune disease and normal, fertile women. the collected endometrial tissue and blood samples will be examined for the cytokines profiling using commercially available elisa kits. the sample size was calculated choosing, as primary outcome, changes in endometrial lif concentration between the disease and control group, which is our main goal. given a type i error of 5%, a maximum of 21 women are needed for each group to reach the desired power of 80% to detect the least changes in concentrations.


Eligibility criteria:
inclusion criteria: study group: \* females with infertility combined with autoimmune disease and in fertility treatment. control group: \* female from couples with severe male infertility and in fertility treatment. exclusion criteria: * language problems to such an extent that the subjects do not understand the scope of the study. * abnormal follicle stimulating hormone (fsh), * abnormal antral follicles count * genital infections * endometriosis * tubal occlusion * polycystic ovarian syndrome
application of 68ga neb pet imaging in the diagnosis and evaluation of lymphatic disorders

Conditions: Lymphatic Disorders

Summary: this is an open-label whole-body pet/ct study for investigating the value of 68ga neb pet imaging in the diagnosis and evaluation of lymphatic disorders including lymphedema, lymphangioma, lymphangioleiomyomatosis, plastic bronchitis, lymphadenopathy caused by rheumatoid arthritis, etc.

no fasting, hydration or other specific preparation was requested on the day of imaging. patients for lymphatic drainage disorders imaging underwent whole-body pet/ct acquisitions 20-40 min after subcutaneously injected into first and second interdigital spaces of both feet or hands of 74-111 mbq (2-3 mci) 68ga-neb with each bed position lasted for 2 min. a mim workstation was used for post-processing. the visual method was used to evaluate the lymphatic system, including the morphology and the distribution of the lymphatic system. semiquantitative methods were applied for image analysis.

Eligibility criteria:
inclusion criteria: * must be able to provide a written informed consent; males and females, ≥18 years old； diagnostic ct or mri suggesting a diagnosis of lymphatic system lesion(s). in suspicion of lymphedema, lymphangioma, lymphangioleiomyomatosis, plastic bronchitis, lymphadenopathy caused by rheumatoid arthritis, etc. exclusion criteria: * females planning to bear a child recently or with childbearing potential; known severe allergy or hypersensitivity to iv radiographic contrast； inability to lie still for the entire imaging time because of cough, pain, etc. inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc. concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.
pain management in elderly patients with or without cognitive frailty hospitalized "algoger"

Conditions: Cognitive Deterioration

Summary: today, the standard treatment is to operate on patients suffering from a fracture of the upper end of the femur. the aim of treatment is to enable immediate mobilization and weight-bearing, and as rapid a return as possible to normal living conditions. surgery is the best treatment option. it maximizes the chances of functional recovery and, by stabilizing the fracture, reduces pain: it is the most effective and longest-lasting analgesic. adequate analgesia in elderly patients with femoral neck fractures has a beneficial effect. in particular, a lower probability of death has been shown in cervical fracture patients receiving opioids than those not receiving them. pain management is a matter of protocol in the upog department of the chu de nîmes. pain prevention appears to improve morbidity and mortality. cognitive fragility, such as neurocognitive disorders, confusion or long-term use of psychotropic drugs, appear to be confounding factors in pain management. the investigators therefore wished to observe whether the presence of cognitive fragility has an impact on pain management on the ward, despite protocol-based management.


Eligibility criteria:
inclusion criteria: * patients aged \> 75 years * hospitalized for a fracture of the upper extremity of the femur at the upog of the chu de nîmes during 2022 exclusion criteria: * opioid allergy * no surgical management of fracture * long-term treatment with high-dose opiates * patient has objected to the use of his or her data.
palmar arch insufficiency as a risk factor for radial artery occlusion after transradial catheterization

Conditions: Coronary Artery Disease

Summary: transradial access (tra) is commonly used in different medical fields due to the superficial position of the radial artery and related advantages. despite its popularity, the incidence and importance of related complications, in particular, radial artery occlusion (rao) remains unclear. further, the only known independent predictors of the radial artery occlusion are the periprocedural anticoagulation as well as the catheter size. the effect of a variable arterial anatomy has so far not been evaluated. in this context, most institutions prefer to evaluate the collateral circulation of the hand, i.e., the arterial palmar arch and forearm circulation before tra. the most commonly employed tests are the modified allen test (mat) or the combination of pulse oximetry and plethysmography according to barbeau.in addition, there are more precise, but still semi-quantitative non-invasive methods for palmar arterial collateral function testing. despite the wealth of these variably accurate and practical tests, invasive and direct hemodynamic measurement of the arterial forearm circulation and its components is lacking. thus, the human physiologic circulatory reference at this site has been unknown so far. further, the need of pre-procedural testing itself can be questioned in light of the reported, widely varying prevalence of rao (1-38%) or critical ischemia (0-0.09%) after tra. the present study investigated in a first step the invasively obtained, pressure-derived hemodynamic function, i.e., the physiology of the human arterial palmar arch and forearm collateral circulation and in a second step the clinical consequences of the variable palmar arterial anatomy.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patient receiving transradial coronary angiography and undergoing evaluation of the palmar arterial arch circulation as a quality control * written informed consent to participate in the follow-up doppler ultrasound examination exclusion criteria: * changed anatomical conditions of the radial artery, e.g. after coronary artery bypass surgery with radial harvest

Keywords: transradial catheterization transradial access radial artery occlusion palmar arch collateral circulation collateral flow index
effectiveness of a four-level chinese emergency triage scale in mainland china

Conditions: Emergencies; Triage

Summary: inter-rater reliability between experts and triage nurses was assessed in 484 emergency patients. the criterion-related validity was evaluated in other 30687 emergency patients, based on emergency department (ed) mortality, the length of stay in ed, the number of discharge, and hospitalization (intensive care/general ward).


Eligibility criteria:
inclusion criteria: * patients, older than 14 years and admitted to the ed, were eligible for this study. exclusion criteria: * gynecologic and obstetric emergencies * patients, who left against medical advice or hadn't been aided by a doctor
effect of yogurt with polydextrose,l acidophilus and b lactis in chronic constipation

Conditions: Constipation

Summary: background and aims:constipation is a frequent complaint and the combination of a prebiotic and probiotics would have a potentially synergic effect on the intestinal transit. the present study therefore aims to investigate the combination of polydextrose (litesse®), l. acidophilus ncfm® and b. lactis hn019 in a yogurt on intestinal transit in subjects who suffer from constipation. methods: patients with constipation were randomly divided into two groups, placebo group (pg) and treatment group (tg), and had to eat 180 ml of unflavored yogurt every morning for 14 days. those in the cg received only yogurt, while the tg received yogurt containing polydextrose, l. acidophilus ncfm® (atcc 700396) and b. lactis hn019 (agal nm97/09513). expect that patients who took a combination of polydextrose has a decrease in the colonic transit time (ctt) when comparing initial and final transit time.


Eligibility criteria:
inclusion criteria: * patients with chonic constipation * agachan between 10 and 20 * bowel transit time with ingestion of 24 radiopaque markers (sitzmarks) and retention of 80% of them on day 5 exclusion criteria: * patients with hypothyroidism * antidepressant users * normal colonic * transit time (24 hrs or less) as well as higher than 96 hours were

Keywords: chronic constipation lactobacillus acidophilus ncfm bifidobacterium lactis hn019
the impact of educational materials on family behavior

Conditions: Overweight; Obesity

Summary: the purpose of the research is to learn whether written materials or handouts that are given to parents are helpful in changing knowledge or behavior.

few written resources for families have been tested in the primary care setting. kid stride (striving to improve diet \& exercise) is an educational booklet designed for parents of overweight children. we hypothesize that this booklet will benefit a small percentage of the overweight and obese population of children as a first-tiered approach to treatment of overweight and obese children.

Eligibility criteria:
inclusion criteria: * children with a bmi greater than or equal to 85% along with a parent. * all subjects must speak english. exclusion criteria: * genetic conditions associated with overweight. * endocrine conditions associated with overweight. * chronic steroid therapy. * current enrollment in a professional weight management program.

Keywords: child
resveratrol for patients with colon cancer

Conditions: Colon Cancer; Cancer

Summary: resveratrol is purported to possess cancer preventive activity, especially for colon cancer, though its mechanisms of action are not well defined. resveratrol is found in the skin of grapes and has anti-oxidative and pro-apoptotic effects on cancer cell lines in vitro. the main dietary sources of resveratrol are grapes, grape products, and red wine, and small amounts may be found in mulberries. a prior report and compelling preliminary data from our laboratory suggest that resveratrol modulates wnt signaling, a signaling pathway which is activated in over 85% of colon cancers. in this proposal, studies were performed to define the actions of resveratrol on the wnt signaling pathway in a clinical trial in which patients with colon cancer received treatment with resveratrol, and correlative laboratory studies examined its effects directly on colon cancer and normal colonic mucosa. these studies provided data on the mechanisms of resveratrol action and provided a foundation for future prevention trials, correlative studies and therapeutic clinical research with this agent.

patients will be treated with a two-week course of resveratrol. the initiation of the treatment will be approximately 14 days before standard of care surgical resection of tumor. resveratrol will be ingested as 20 mg pills or in the form of freeze-dried grape extract which is prepared by the california table grape commission used under gmp guidelines for human consumption. the first two patients receiving resveratrol will be treated at a dose of 20 mg/day, the third and fourth patients at a dose of 80 mg/day, and the fifth and sixth patients with a dose of 160 mg/day. all patients receiving grape extract will receive 125 mg/day that will have to be mixed with one 8 oz glass of water. there will be no dose adjustments. if a patient has any side effects which are attributed to the resveratrol, it will be discontinued.

Eligibility criteria:
inclusion criteria: * patients diagnosed with colon cancer by colonoscopic biopsy and tissue obtained under uci04-05. * patients with a plan for surgical resection at ucimc within 2-4 weeks of enrollment. exclusion criteria: * surgical resection to be performed at a facility other than ucimc. * patients under 18 years of age.

Keywords: colon cancer resveratrol clinical trial wnt signaling grapes cancer prevention
efficacy of early intensive rosuvastatin therapy in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (the rosemary trial)

Conditions: ST-segment Elevation AMI

Summary: objectives: an investigator-initiated, double-blind, randomized, placebo-controlled, multi-center study to evaluate the efficacy of early intensive rosuvastatin therapy (rosuvastatin 40 mg for pre-pci loading and 7 days post pci and 10 mg daily thereafter) versus low dose conventional statin therapy (placebo for pre-pci loading and rosuvastatin 10 mg daily after primary pci) on infarct size measured by cardiac mri and clinical outcomes in stemi patients undergoing primary percutaneous coronary intervention (pci). hypothesis: the infarct size in the early high dose rosuvastatin group is smaller than that of the control patients treated with low does conventional statin therapy.


Eligibility criteria:
inclusion criteria: 1. patient had the symptoms of acute myocardial infarction within 12 hours with st-segment elevation of more than 1 mm in at least two contiguous leads of ekg or new onset lbbb. 2. male or female over 20 years of age 3. signed written informed consent to participate in the study exclusion criteria: 1. congestive heart failure (nyha class iii or iv) or lvef \<35%. 2. clinically significant heart disease requiring cabg, cardiac transplantation, surgical repair and/or replacement during the course of the study. 3. previous mi or cabg 4. known serious or hypersensitivity reactions to statin, antiplatelet agents (aspirin or clopidogrel), or heparin. 5. known familial hypercholesterolemia 6. known skeletal muscle disease 7. known active liver disease such as hepatitis or liver cirrhosis (except for fatty liver) 8. renal failure (cr \>2.0 mg/dl) 9. secondary causes of hyperlipoproteinemia: uncontrolled primary hypothyroidism, and/or nephrotic syndrome 10. non-cardiac comorbidity with a life expectation \< 1 year 11. contraindications to cmri (eg, implanted pacemaker or cardiac defibrillator, claustrophobia, etc.) 12. pregnant or lactating women or women of childbearing potential 13. participation in any investigational drug or device study within 30 days prior to study entry
comparison of doses of acetylsalicylic acid in women with previous history of preeclampsia

Conditions: Pre-Eclampsia; Fetal Growth Retardation; Premature Birth; Placental Insufficiency

Summary: placental insufficiency is the source of preeclampsia (pe) and intrauterine growth retardation (iugr). current data demonstrate a significant beneficial effect of prophylactic use of aspirin on the recurrence of placental insufficiency and its complications, mainly preeclampsia, when started early in pregnancy. however, there is a significant heterogeneity in medical practice in canada and around the world in terms of the dose of aspirin used. the objectives of this study are: 1) evaluate whether a dose of 160 mg of aspirin is associated with greater improvement in placental function assessed by biochemistry (sflt-1 and endoglin) and ultrasound (uterine artery doppler) than a dose of 80 mg in women with a history of pe, 2) assess whether the change is dependent on platelet aggregation measured by a test used in several canadian centers (pfa-100).

many studies suggest that aspirin (acetylsalicylic acid) at low dose significantly reduces the incidence of preeclampsia. more recent data have shown that, when administered before 16 weeks of pregnancy, aspirin can prevent over 50% of preeclampsia, severe preeclampsia, and iugr but also a significant proportion of the rate of preterm births. current data also demonstrate a beneficial effect of prophylactic use of aspirin when started early in pregnancy in populations composed of high-risk patients with a history of preeclampsia and / or other pregnancy complications related to poor placental function. beside, many clinicians are already using aspirin in the context of a proven benefit. however, the usual dose prescribed in canada today is 80 mg while the most favorable studies have used a slightly higher dose of aspirin (100 mg). moreover, it has been demonstrated that the time of day during which aspirin was administered was also a very important factor regarding the effect on blood pressure and adverse outcomes of the majority of pregnancy. yet the majority of studies in this context have not specified the time of day at which aspirin was or had been taken, possibly underestimating the effect thereof.

Eligibility criteria:
inclusion criteria: * gestational age between 10 0 / 7 and 13 6 / 7 weeks * history of preeclampsia (as defined by the society of obstetricians and gynaecologists of canada) confirmed by medical records exclusion criteria: * negative fetal heart * multiple pregnancy * anaphylactic allergy to lactose * kown coagulopathy (antithrombin iii deficiency, factor v leiden, antiphospholipid syndrome, the prothrombin mutation, deficiency of protein s or protein c) * use of heparin or other anticoagulants. * contraindications to aspirin * severe fetal abnormality (cystic hygroma, nuchal translucency\> 95th percentile, anencephaly, etc.) * history or active peptic ulcer